{"id":"NCT00100659","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","briefTitle":"PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C","officialTitle":"Pegylated Interferon +/- Ribavirin for Children With Hepatitis C","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-12","primaryCompletion":"2008-08","completion":"2010-02","firstPosted":"2005-01-05","resultsPosted":"2013-07-01","lastUpdate":"2018-10-24"},"enrollment":114,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis C"],"interventions":[{"type":"DRUG","name":"Pegylated Interferon/ribavirin","otherNames":[]}],"arms":[{"label":"Pegylated interferon/ribavirin","type":"ACTIVE_COMPARATOR"},{"label":"Pegylated interferon/placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the safety and efficacy of peginterferon alfa-2a (PEG-2a) in combination with ribavirin (RV) and PEG-2a alone for the treatment of chronic hepatitis C virus (CHC) infection in children.\n\nThe purpose of this study is also to determine whether PEG-2a in combination with RV or PEG-2a alone will result in a longer response rate in children with CHC.","primaryOutcome":{"measure":"Sustained Viral Response (SVR)","timeFrame":"at least 24 weeks after stopping treatment.","effectByArm":[{"arm":"PEG/RV","deltaMin":29,"sd":null},{"arm":"PEG/Placebo","deltaMin":12,"sd":null}],"pValues":[]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":27},"locations":{"siteCount":11,"countries":["United States"]},"refs":{"pmids":["18042575","21351116","21036173","18167062","20512062","25313851","26284539","23439301","22383118"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":55},"commonTop":["Flu-like symptoms","Gastrointestinal symptoms","Headache","Injection site reaction","Joint and muscle aches"]}}